Literature DB >> 19460418

Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression.

Dingcheng Gao1, Daniel Nolan, Kevin McDonnell, Linda Vahdat, Robert Benezra, Nasser Altorki, Vivek Mittal.   

Abstract

Emerging evidence indicates that bone marrow (BM)-derived endothelial progenitor cells (EPCs) contribute to angiogenesis-mediated growth of certain tumors in mice and human. EPCs regulate the angiogenic switch via paracrine secretion of proangiogenic growth factors and by direct luminal incorporation into sprouting nascent vessels. While the contributions of EPCs to neovessel formation in spontaneous and transplanted tumors and to the metastatic transition have been reported to be relatively low, remarkably, specific EPC ablation in vivo has resulted in severe angiogenesis inhibition and impaired primary and metastatic tumor growth. The existence of a BM reservoir of EPCs, and the selective involvement of EPCs in neovascularization, have attracted considerable interest because these cells represent novel target for therapeutic intervention. In addition, EPCs are also being used as pharmacodynamic surrogate markers for monitoring cancer progression, as well as for optimizing efficacy of anti-angiogenic therapies in the clinic. This review will focus primarily on recent advances and emerging concepts in the field of EPC biology and discuss ongoing debates involving the role of EPCs in tumor neovascularization. For detailed information on the in vitro characterization of EPCs contribution to non-tumor pathologies, the reader is directed towards several excellent reviews and publications [F. Bertolini, Y. Shaked, P. Mancuso and R.S. Kerbel, Nat. Rev., Cancer 6 (2006) 835-845. [1]] [J.M. Hill, T. Finkel and A.A. Quyyumi, Vox Sang. 87 Suppl 2 (2004) 31-37. [2]] [A.Y. Khakoo and T. Finkel, Annu. Rev. Med. 56 (2005) 79-101. [3]] [H.G. Kopp, C.A. Ramos and S. Rafii, Curr. Opin. Hematol. 13 (2006) 175-181. [4]; K.K. Hirschi, D.A. Ingram and M.C. Yoder, Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1584-1595. [5]; F. Timmermans, J. Plum, M.C. Yoder, D.A. Ingram, B. Vandekerckhove and J. Case, J. Cell. Mol. Med. 13 (2009) 87-102. [6]] and reviews by Bertolini, Voest and Yoder in this issue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19460418      PMCID: PMC3649840          DOI: 10.1016/j.bbcan.2009.05.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  78 in total

1.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.

Authors:  Hiroaki Nozawa; Christopher Chiu; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-04       Impact factor: 11.205

2.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

Authors:  M Peichev; A J Naiyer; D Pereira; Z Zhu; W J Lane; M Williams; M C Oz; D J Hicklin; L Witte; M A Moore; S Rafii
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

3.  Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart.

Authors:  Elina Minami; Michael A Laflamme; Jeffrey E Saffitz; Charles E Murry
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

Review 4.  Assessing identity, phenotype, and fate of endothelial progenitor cells.

Authors:  Karen K Hirschi; David A Ingram; Mervin C Yoder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

5.  Circulating vascular progenitor cells do not contribute to compensatory lung growth.

Authors:  Robert Voswinckel; Tibor Ziegelhoeffer; Matthias Heil; Sawa Kostin; Georg Breier; Tanja Mehling; Rainer Haberberger; Matthias Clauss; Andreas Gaumann; Wolfgang Schaper; Werner Seeger
Journal:  Circ Res       Date:  2003-07-24       Impact factor: 17.367

6.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.

Authors:  Patrizia Mancuso; Marco Colleoni; Angelica Calleri; Laura Orlando; Patrick Maisonneuve; Giancarlo Pruneri; Alice Agliano; Aron Goldhirsch; Yuval Shaked; Robert S Kerbel; Francesco Bertolini
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

7.  Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.

Authors:  Yulong He; Iiro Rajantie; Maritta Ilmonen; Taija Makinen; Marika J Karkkainen; Paula Haiko; Petri Salven; Kari Alitalo
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 8.  CD133: molecule of the moment.

Authors:  D Mizrak; M Brittan; M R Alison
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

9.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

10.  A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.

Authors:  Dan G Duda; Kenneth S Cohen; David T Scadden; Rakesh K Jain
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

View more
  59 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung.

Authors:  Zhichao Zhou; Keri Schadler Stewart; Ling Yu; Eugenie S Kleinerman
Journal:  Angiogenesis       Date:  2010-12-24       Impact factor: 9.596

3.  Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment.

Authors:  Yoon-Jin Lee; Daniel L Karl; Ugwuji N Maduekwe; Courtney Rothrock; Sandra Ryeom; Patricia A D'Amore; Sam S Yoon
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

4.  Celastrol, an active constituent of the TCM plant Tripterygium wilfordii Hook.f., inhibits prostate cancer bone metastasis.

Authors:  K Kuchta; Y Xiang; S Huang; Y Tang; X Peng; X Wang; Y Zhu; J Li; J Xu; Z Lin; T Pan
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-02-14       Impact factor: 5.554

5.  Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma.

Authors:  Cong Hua; Gang Zhao; Yan Feng; Hongyan Yuan; Hongmei Song; Li Bie
Journal:  J Neurotrauma       Date:  2015-08-06       Impact factor: 5.269

6.  Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer.

Authors:  T A Zikos; A D Donnenberg; R J Landreneau; J D Luketich; V S Donnenberg
Journal:  Cancer Immunol Immunother       Date:  2011-03-05       Impact factor: 6.968

7.  Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans.

Authors:  Kyoko Kawasaki; Julia Freimuth; Dominique S Meyer; Marie M Lee; Akiko Tochimoto-Okamoto; Michael Benzinou; Frederic F Clermont; Gloria Wu; Ritu Roy; Tom G W Letteboer; Johannes Kristian Ploos van Amstel; Sophie Giraud; Sophie Dupuis-Girod; Gaeten Lesca; Cornelius J J Westermann; Robert J Coffey; Rosemary J Akhurst
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-08       Impact factor: 11.205

Review 8.  Bevacizumab and breast cancer: current therapeutic progress and future perspectives.

Authors:  Sherry X Yang
Journal:  Expert Rev Anticancer Ther       Date:  2009-12       Impact factor: 4.512

9.  Conditioned media from human ovarian cancer endothelial progenitor cells induces ovarian cancer cell migration by activating epithelial-to-mesenchymal transition.

Authors:  L Teng; S Peng; H Guo; H Liang; Z Xu; Y Su; L Gao
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

10.  CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.

Authors:  L Vroling; J S W Lind; R R de Haas; H M W Verheul; V W M van Hinsbergh; H J Broxterman; E F Smit
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.